

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Lin, *et al.*

**Serial No.:** 08/182,183

**Filed:** May 23, 1994

**For:** GLIAL CELL LINE-DERIVED  
NEUROTROPHIC FACTOR

**Group Art Unit:** 1645

**Examiner:** Robert C. Hayes

**Docket No.:** SYNE-225-E

**Date:** August 15, 2000

#57 1/2

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE  
PATENTING REJECTION OVER A PRIOR PATENT**

Assistant Commissioner For Patents  
Washington, DC 20231

Sir:

Petitioner, Amgen Inc., is the owner of the entire interest in the instant application.


Petitioner hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of U. S. Patent No. 6,093,802, and hereby agrees that any patent so granted on said above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U. S. Patent No. 6,093,802, this agreement to run with any patent granted on said above-identified application and to be binding upon the grantee, its successors, or assigns.

Petitioner does not disclaim any terminal part of any patent granted on said above-identified application that would extend to the full statutory term as presently shortened by any terminal disclaimer of U. S. Patent No. 6,093,802 in the event that said U. S. Patent No. 6,093,802 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a re-examination certificate, is

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

August 15, 2000  
Date




reissued, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Copies of the assignment documents in the chain of title from the original owner to assignee were filed in the present case on January 14, 1998, and were recorded in the U. S. Patent and Trademark Office at reel 8371 and frame 0136.

The undersigned has reviewed the attached assignment documents and certifies that, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Daniel R. Curry  
Attorney for Applicants  
Registration No: 32,727  
Phone: (805) 447-8102  
Date: August 15, 2000

Please send all future correspondence to:

U.S. Patent Operations/DRC  
Dept. 4300 M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799